Form 4: ImmunityBio CFO Sachs Exercises RSUs, Sells for Tax

ImmunityBio's Chief Financial Officer, David C. Sachs, reported the vesting and exercise of restricted stock units and subsequent tax-related share disposition.

Summary

• David C. Sachs, Chief Financial Officer of ImmunityBio, Inc. (IBRX), reported transactions on February 10, 2026.
• Sachs acquired 82,236 shares of common stock upon the vesting of restricted stock units (RSUs).
• Concurrently, 42,643 shares were disposed of to cover tax withholding obligations at a price of $6.93 per share.
• Following these transactions, Sachs directly owns 280,175 shares of common stock.
• Sachs also holds 164,474 restricted stock units, which are subject to a vesting schedule over three years, with the vesting commencement date being February 10, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and continued insider ownership, without significant new operational or financial information.

Positives

• CFO Sachs continues to hold a significant number of common shares (280,175) and additional RSUs (164,474), indicating continued alignment with shareholder interests.

Negatives

• A portion of the vested shares (42,643) was sold to cover tax liabilities, which is a common practice but reduces direct ownership.

Future Outlook

The filing details the vesting schedule for the remaining restricted stock units held by the CFO, indicating future share issuances contingent on continued service through February 10, 2028 (third anniversary of vesting commencement date).

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures. While they provide transparency into executive compensation and ownership, they typically do not offer insights into broader industry trends or competitive positioning. The vesting of RSUs and subsequent tax-related sales are common events in executive compensation structures across various industries, including biotechnology.

Comparison to Industry Standards

• This Form 4 reports standard RSU vesting and tax withholding practices, which are common across publicly traded companies, particularly in the biotechnology sector.
• For example, executives at companies like Amgen (AMGN) or Gilead Sciences (GILD) frequently report similar transactions as part of their equity compensation plans.
• The specific share price of $6.93 for tax withholding is company-specific and not directly comparable to industry benchmarks without broader context of IBRX's stock performance relative to peers.

Stakeholder Impact

• Shareholders: Provides transparency on executive ownership and compensation, showing continued alignment of the CFO with shareholder interests through equity holdings.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices.

Next Steps

• Future vesting of 164,474 restricted stock units on the first, second, and third anniversaries of February 10, 2025, contingent on continued service.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of insider transactions related to executive compensation (RSU vesting and tax withholding). It does not contain new material information regarding the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The continued significant equity holdings by the CFO are a positive for alignment, but the transaction itself is not a catalyst for a 'buy' or 'sell' decision.

Keywords

ImmunityBio, IBRX, Form 4, Insider Trading, Restricted Stock Units, RSU, CFO, David C. Sachs, Stock Vesting, Tax Withholding